In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Rebate Reform: Big Changes Are Looming For The US Drug Market

Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system. Yet, increasingly it seems the US drug market is poised for a big shake up when it comes to the way pharmaceuticals manufacturers price their drugs, negotiate market access with payers, and pay back-end discounts to offset the cost of their products. 

United States Market Access Pricing Strategies

Immuno-Oncology: Unicorns, China And The Perfect Storm

There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets.

ImmunoOncology Market Intelligence Cancer

The Oncology Burden Of Proof: Learning From The PD-1 Market

As more and more immuno-oncology products reach the market, the sustainability challenge persists: biopharmaceutical companies are seeking fair reimbursement deals that recognize their innovations, and struggling health care systems worldwide are pushing the burden of proof back onto the shoulders of drug developers.

Market Access ImmunoOncology Cancer

Room At The Top? The Case For A Chief Value Officer

As pharmaceutical pricing and market access functions face increasing scrutiny from stakeholders, it is time for C-suite leaders to focus more on value creation, communication, and governance in order to articulate the value of not only of their therapies but also industry contribution at-large.

Leadership Strategy BioPharmaceutical
Advertisement

Datamonitor Healthcare Podcasts


Recent Tweets from In Vivo


Tech Advances Trigger Transformation For Pharma

As the costs of bringing drugs to market continue to rise and pricing pressure bites, pharma is looking for new ways to create value and drive efficiencies, including partnering with tech giants and agile start-ups to create technology solutions that lead to improved and diversified revenue streams.

Read More

Case Study: Broad Thinking Yields Big Results

There are numerous details when considering product packaging that require both creative thinking and feature prioritization. Rather than developing a standard solution for the current need, it’s imperative to think broadly and design options that are cost-effective, simplify operations and save time and/or resources.

Read Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Aptar's Focus On Digital Connectivity Presents New Drug Delivery Opportunities

Digital connectivity is the future of drug delivery, according to Aptar Pharma, which recently deepened its partnering commitment with digital therapeutics software developer Propeller Health. But it stresses that value is the key, and not connectivity for its own sake.

Growth Respiratory

‘Going Digital’ Is Changing Pharma’s Processes, People And Culture

Digital must become a core capability for pharma if it is to remain competitive. New technologies bring faster innovation cycles, but demand new kinds of expertise and partnerships that threaten traditional hierarchies and mindsets. The rewards, for pharma, are most likely to come from improved efficiency and stronger relationships with stakeholders, rather than from digital end-products.

Digital Health Artificial Intelligence

Vericel: Rebooting A Failing Business With Unloved Assets

Following the acquisition of cell therapy assets from Sanofi, which Sanofi had secured in its purchase of Genzyme, Aastrom Biosciences changed its name to Vericel, doubled down in cell therapy and relocated to Massachusetts. Since then it has seen its revenues grow 12% per year from just under $43 million in 2013 to just under $64 million in 2017. The target for 2020: drive revenues north of $100 million.

Business Strategies Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Pharma’s Digital Directive: Not If, But How

Data science and data analytics offer operational advantages throughout large organizations. And the pharma should approach digital technology pragmatically, first applying the tools to what it already does.

Digital Health Innovation

Aetion: Sealing The Deal With Payers On Real-World Research

As biopharma’s embrace of real-world evidence (RWE) gathers speed, In Vivo looks at one company that is using a mix of prestigious academic, government and non-profit partners to build a credible foundation for acceptance of this research tool in the wider commercial space. 

Innovation Strategy

A Chance To Own The Venous Space: BTG Acquires Novate

Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, bu BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings. 

Innovation Surgical Procedures

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On the Move, Oct 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market

Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.

Leadership Research and Development Strategies

Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies

Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.

Asia Pacific Regenerative Medicine

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Brexit No Certain Thing For European Medtech Groups Desperate To Plan Futures

Medtech stakeholders were reminded at the UK's largest regulatory forum that, for business in general, and medical technology manufacturers in particular, those willing to make the best of Brexit are still having to work in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.

Brexit Market Access

The Advantages Of Providing Access To Unlicensed Medicines

Providing access to novel medicines through early access programs or supplying markets where medicines remain unlicensed has key benefits for the innovative drug development industry; revealing market insights and strategic opportunities.

Market Access Pricing Strategies

Spark Therapeutics: Calculating The Price Of A Cure

John Furey, chief operating officer of Spark Therapeutics, discusses how the company has created a value framework for the first US-approved gene therapy to treat an incurable, inherited genetic condition: Luxturna  (voretegene neparvovec-ryzl).  He also highlights the remaining access and reimbursement challenges for this novel gene therapy, which is approved specifically for treatment of inherited retinal blindness from a rare RPE65 gene mutation. 
Market Access Strategy

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: September 2018

In a $663 million alliance, Takeda and Molecular Templates will co-develop CD38-targeted engineered toxin bodies for multiple sclerosis and other diseases.  Medtronic paid $1.3 billion to buy the rest of Israeli device maker Mazor Robotics. Biopharma financing was up from the previous month, thanks to a strong showing of FOPOs.

Deals Market Intelligence

The Emergence Of IO

The approval of first-generation checkpoint inhibitors, Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo in the second half of 2014, catalyzed a wave of deal-making, not only around other checkpoint inhibitors, but also for molecules and technologies that could offer synergistic benefits when used in combination with these drugs. 

ImmunoOncology Market Intelligence

Deals Shaping The Medical Industry, October 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2018. 

Market Intelligence Deals
UsernamePublicRestriction

Register

Advertisement